Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data
Source Entity
Dominic-Madori Davis
Women's health startup Evvy has secured $40 million in Series B funding led by Catalio Capital Management. The company aims to expand its vaginal microbiome research and diagnostic testing services using its proprietary mNGS technology.
Advancing Women’s Health: Evvy’s $40 Million Series B Milestone
The women’s health technology sector has reached a significant milestone with the announcement that Evvy, a company dedicated to vaginal microbiome research, has successfully raised $40 million in a Series B funding round. Led by Catalio Capital Management, this capital infusion highlights a growing investor appetite for precision medicine and data-driven healthcare solutions specifically tailored to the female demographic. By focusing on the vaginal microbiome, Evvy is addressing a long-standing gap in clinical research, where women’s health conditions have historically been under-researched and underserved.
The Technology Behind the Swab
Founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy has distinguished itself through its proprietary diagnostic capabilities. The company operates what it describes as the world’s only at-home CLIA-certified and CLEP-certified metagenomic next-generation sequencing (mNGS) test. This technology allows for a comprehensive analysis of vaginal microbes from a single swab, providing a level of granular data that was previously difficult to obtain in a home-testing environment. By leveraging mNGS, Evvy can identify a wide array of microorganisms, moving beyond traditional, limited diagnostic methods.
Operational Workflow and Clinical Integration
The user experience is designed for seamless integration between home-based collection and professional medical oversight. Patients mail their samples directly to Evvy’s laboratory, where the mNGS sequencing process occurs. Once the data is processed, the results are funneled through a robust pipeline: the findings are reviewed by clinicians registered on the Evvy platform and subsequently made available to the patient via a secure online health portal. This model bridges the gap between direct-to-consumer testing and clinical decision-making.
Personalized Care and Diagnostic Interpretation
A core component of Evvy’s value proposition is its commitment to moving beyond raw data to actionable clinical insights. When a patient accesses their test results, the platform provides a diagnosis, a professional clinical interpretation, and a clear, personalized roadmap for next steps. This includes access to prescription care when clinically relevant. By providing this end-to-end service, Evvy ensures that patients are not left to interpret complex microbiological data alone, but are instead guided through their health journey by medical professionals.
Broader Implications for Healthcare
Evvy’s focus on the vaginal microbiome represents a paradigm shift in how we understand women’s health, moving from broad symptoms to precise molecular diagnostics. The microbiome is increasingly recognized as a key indicator of overall health, and by building a proprietary, large-scale database of vaginal microbial data, Evvy is positioned to contribute significantly to the future of gynecological research. This investment suggests that the industry is shifting toward prioritizing long-term health outcomes over reactionary treatments, potentially setting a new standard for how at-home diagnostics are integrated into the primary care ecosystem.